CO5690533A2 - Composicion farmaceutica que comprende micro-particulas de octreotida - Google Patents

Composicion farmaceutica que comprende micro-particulas de octreotida

Info

Publication number
CO5690533A2
CO5690533A2 CO05050166A CO05050166A CO5690533A2 CO 5690533 A2 CO5690533 A2 CO 5690533A2 CO 05050166 A CO05050166 A CO 05050166A CO 05050166 A CO05050166 A CO 05050166A CO 5690533 A2 CO5690533 A2 CO 5690533A2
Authority
CO
Colombia
Prior art keywords
particles
pharmaceutical composition
micro
includes octreotide
octreotide
Prior art date
Application number
CO05050166A
Other languages
English (en)
Inventor
Oliver Lambert
Michael Ausborn
Holger Petersen
Rolf Loffler
Jean Daniel Bonny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32299717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5690533(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0226993A external-priority patent/GB0226993D0/en
Priority claimed from GB0227883A external-priority patent/GB0227883D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5690533A2 publication Critical patent/CO5690533A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Una composición farmacéutica que comprende micro-partículas de acetato de octreotida de polímero lineal de poli-(Iáctido-co-glicólido), en donde el polímero contiene menos del 1 por ciento de aceite de silicona o heptano, y de preferencia está libre de aceite de silicona o heptano.
CO05050166A 2002-11-19 2005-05-24 Composicion farmaceutica que comprende micro-particulas de octreotida CO5690533A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226993A GB0226993D0 (en) 2002-11-19 2002-11-19 Organic compounds
GB0227883A GB0227883D0 (en) 2002-11-29 2002-11-29 Organic compounds

Publications (1)

Publication Number Publication Date
CO5690533A2 true CO5690533A2 (es) 2006-10-31

Family

ID=32299717

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05050166A CO5690533A2 (es) 2002-11-19 2005-05-24 Composicion farmaceutica que comprende micro-particulas de octreotida

Country Status (17)

Country Link
US (6) US20040097419A1 (es)
EP (2) EP1565161A2 (es)
JP (2) JP2006514927A (es)
KR (2) KR101146471B1 (es)
AU (3) AU2003293700A1 (es)
BR (1) BR0316421A (es)
CA (1) CA2501978C (es)
CO (1) CO5690533A2 (es)
EC (1) ECSP055800A (es)
ES (1) ES2577613T3 (es)
HK (1) HK1161123A1 (es)
MX (1) MXPA05005388A (es)
NO (1) NO20052952L (es)
PL (1) PL376015A1 (es)
PT (1) PT2377519E (es)
RU (2) RU2404748C2 (es)
WO (1) WO2004045633A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570960C (en) 2004-06-17 2013-10-01 Valera Pharmaceuticals, Inc. Compositions and methods for treating central precocious puberty
KR101231856B1 (ko) * 2004-08-12 2013-02-08 큐피에스 엘엘씨 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
AU2005316545A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
EP1787658B1 (en) 2005-11-10 2012-03-14 CHEMI S.p.A. Sustained release formulations of somatostatin analogue inhibitors of growth hormone
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
RU2463079C2 (ru) * 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
MX2011000036A (es) 2008-06-25 2011-02-22 Endo Pharmaceuticals Solutions Implante de octreotida que tiene un agente de liberacion.
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
JP5769626B2 (ja) 2008-09-18 2015-08-26 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 溶媒および塩を用いるマイクロカプセル封入プロセス
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
AU2014228460B2 (en) * 2013-03-15 2018-11-01 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
CN106727448B (zh) * 2016-12-12 2020-10-13 广州中大南沙科技创新产业园有限公司 醋酸奥曲肽干粉吸入制剂及其制备方法
JP7170670B2 (ja) 2017-02-27 2022-11-14 ユニヴァーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイアー エデュケイション 抗精神病組成物及び治療方法
WO2019155396A1 (en) * 2018-02-07 2019-08-15 Dr. Reddy's Laboratories Limited Sustained release microspheres with low initial burst and methods of preparation thereof
KR101936040B1 (ko) 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE2512T1 (de) 1979-11-27 1983-03-15 Sandoz Ag Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
DE3032345C2 (de) * 1980-08-28 1984-06-28 Mathias 4815 Schloss Holte Mitter Lagerung einer Rakel mit seitlich außerhalb der Schablone eines Siebdruckwerkes angeordneten Lagern
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
AU5741590A (en) * 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9805417D0 (en) * 1998-03-14 1998-05-06 Core Technologies Limited Production of microparticles
US6204308B1 (en) * 1999-03-01 2001-03-20 Novartis Ag Organic compounds
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
AU2002232824A1 (en) * 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents

Also Published As

Publication number Publication date
CA2501978A1 (en) 2004-06-03
CA2501978C (en) 2013-12-17
MXPA05005388A (es) 2005-08-03
KR101146471B1 (ko) 2012-05-21
HK1161123A1 (zh) 2012-08-24
PL376015A1 (en) 2005-12-12
RU2010144614A (ru) 2012-05-10
US20220273574A1 (en) 2022-09-01
AU2011200966A1 (en) 2011-03-24
KR101240071B1 (ko) 2013-03-06
RU2404748C2 (ru) 2010-11-27
NO20052952L (no) 2005-08-15
KR20050086708A (ko) 2005-08-30
EP1565161A2 (en) 2005-08-24
JP5784402B2 (ja) 2015-09-24
US20040097419A1 (en) 2004-05-20
US20200009056A1 (en) 2020-01-09
PT2377519E (pt) 2016-06-09
US20140323415A1 (en) 2014-10-30
JP2006514927A (ja) 2006-05-18
AU2003293700A1 (en) 2004-06-15
JP2011256185A (ja) 2011-12-22
EP2377519A3 (en) 2011-11-23
WO2004045633A2 (en) 2004-06-03
AU2011200966B2 (en) 2013-08-01
AU2008200018B2 (en) 2010-12-09
AU2008200018A1 (en) 2008-01-31
RU2005119632A (ru) 2006-05-10
WO2004045633A3 (en) 2005-01-13
EP2377519A2 (en) 2011-10-19
US20070122485A1 (en) 2007-05-31
KR20120032537A (ko) 2012-04-05
US20170281548A1 (en) 2017-10-05
NO20052952D0 (no) 2005-06-16
ECSP055800A (es) 2005-08-11
EP2377519B1 (en) 2016-03-23
ES2577613T3 (es) 2016-07-15
BR0316421A (pt) 2005-10-11

Similar Documents

Publication Publication Date Title
CO5690533A2 (es) Composicion farmaceutica que comprende micro-particulas de octreotida
ATE478120T1 (de) Thermoplastische zusammensetzungen
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
BR0111520A (pt) Tiazina oxazolidinona usada como agente antimicrobiano
DE60222454D1 (de) Thermoplastische polyurethan-silikon-elastomere
SE0102315D0 (sv) Compounds
BR9814743A (pt) Tablete de detergente
UY27346A1 (es) Composiciones farmaccuticas que contienen conjuntos de polemero y frrmaco.
BR0313549A (pt) Composições de poliolefina plastificadas
ECSP045429A (es) Combinacion de compuestos organicos
AR000560A1 (es) Una estructura absorbente elastomérica y el producto absorbente descartable que contiene dicha estructura
BRPI0402760A (pt) Composição microbicida
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
IL165809A0 (en) Substituted heterocyclic compounds and pharmaceutical compositions containing the same
MXPA06010767A (es) Composicion farmaceutica anhidra que asocia un agente siliconado y principio activo solubilizado.
BR0316616A (pt) Emplastro térmico
ATE449794T1 (de) Polymerzusammensetzung enthaltend ein polymer mit polymergradient morphologie
ATE503774T1 (de) Photohärtbare michaeladditionspolymere
DK1406505T3 (da) Bionedbrydelig gummibase, som udviser forbedrede egenskaber
ATE496109T1 (de) Umsetzungsprodukte von mercaptobenzothiazolen, mercaptothiazolinen und mercaptobenzimidazolen mit epoxiden als schmiermitteladditive
BR0313767A (pt) Artigo de proteção da vida resistente à penetração
HN1998000088A (es) Tratamiento de resistencia a la insulina
DE60312211D1 (de) Haarbehandlungsmittel
BR0212931A (pt) Composição farmacêutica de liberação prolongada contendo metformina
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT

Legal Events

Date Code Title Description
FA Application withdrawn